Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-12 2:05 pm Purchase | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | JANUS HENDERSON GROUP PLC JHG | 1,279,975 4.300% | 279,899 (+27.99%) | Filing History |
| 2024-02-09 4:29 pm Purchase | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I, LLC | 2,678,209 9.000% | 1,388,889 (+107.72%) | Filing History |
| 2024-02-09 07:06 am Sale | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Adjuvant Global Health Technology Fund L.P. | 2,473,500 8.300% | -123,880 (-4.77%) | Filing History |
| 2023-07-25 4:19 pm Purchase | 2023-06-26 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I, LLC | 1,289,320 6.600% | 1,289,320 (New Position) | Filing History |
| 2023-07-05 4:55 pm Purchase | 2023-06-26 | 13G | AN2 Therapeutics, Inc. ANTX | JANUS HENDERSON GROUP PLC JHG | 1,000,076 5.100% | 1,000,076 (New Position) | Filing History |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | RA CAPITAL MANAGEMENT LLC | 3,773,517 19.500% | 106,854 (+2.91%) | Filing History |
| 2023-02-14 11:45 am Sale | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 1,563,963 8.100% | -52,702 (-3.26%) | Filing History |
| 2023-02-14 08:26 am Sale | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | CITADEL ADVISORS LLC | 1,336,993 6.900% | -24 (-0.00%) | Filing History |
| 2023-02-13 5:06 pm Purchase | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | PFIZER INC PFE | 1,362,499 7.020% | 1,362,499 (New Position) | Filing History |
| 2023-02-13 4:45 pm Purchase | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Brii Biosciences Limited | 1,048,479 5.400% | 1,048,479 (New Position) | Filing History |
| 2023-02-10 4:57 pm Purchase | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Adjuvant Global Health Technology Fund L.P. | 2,597,380 13.400% | 2,597,380 (New Position) | Filing History |
| 2022-04-08 4:31 pm Purchase | 2022-03-29 | 13G | AN2 Therapeutics, Inc. ANTX | RA CAPITAL MANAGEMENT LLC | 3,666,663 19.600% | 3,666,663 (New Position) | Filing History |
| 2022-04-08 4:11 pm Purchase | 2022-03-29 | 13G | AN2 Therapeutics, Inc. ANTX | CITADEL ADVISORS LLC | 1,337,017 7.100% | 1,337,017 (New Position) | Filing History |
| 2022-04-04 4:38 pm Purchase | 2022-03-25 | 13G | AN2 Therapeutics, Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 1,616,665 8.600% | 1,616,665 (New Position) | Filing History |